Effect of in vitro fertilization treatment and subsequent pregnancy on the protein C pathway

British Journal of Haematology

Volumn 115, Issue 2, 2001, Pages 400-407

  Curvers, J ^a   Nap, A W ^b   Thomassen, M C L G D ^a   Nienhuis, S J ^b   Hamulyak K ^b   Evers, J L H ^b   Tans, G ^a   Rosing, J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

APC resistance; IVF cycle; Oestrogens; Oral contraceptives; Venous thrombosis

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT PROTEIN; ESTRADIOL; ORAL CONTRACEPTIVE AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROGESTERONE; PROTEIN S; SEX HORMONE;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FEMALE; FERTILIZATION IN VITRO; HUMAN; NORMAL HUMAN; OVARY HYPERSTIMULATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; BLOOD COAGULATION; BLOOD SPECIMEN COLLECTION; ESTRADIOL; FEMALE; FERTILIZATION IN VITRO; HUMANS; OVULATION INDUCTION; PREGNANCY; PROGESTERONE; PROTEIN C; PROTEIN C INHIBITOR; PROTEIN S;

EID: 0035726554     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.03118.x     Document Type: Article

References (36)

1. Risk of thromboembolism in relation to an in-vitro fertilization programme: Three case reports
2. Hemostasis parameters during ovarian stimulation for in vitro fertilization: Results of a prospective study
3. Superior vena cava thrombosis after in vitro fertilization
4. Do lowered factor VII levels at extremely high endogenous oestradiol levels protect against thrombin formation?
5. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy
6. Acquired APC resistance and oral contraceptives: Differences between two functional tests
7. Risk of venous thromboembolism in users of hormone replacement therapy
8. Laboratory diagnosis of APC-resistance: A critical evaluation of the test and the development of diagnostic criteria
9. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis
10. Progestogen potency in oral contraceptive pills
11. APC resistance and other haemostatic variables during pregnancy and puerperium
12. Effects of oral contraceptives on haemostasis variables
13. Importance of levonorgestrel dose in oral contraceptives for effects on coagulation
14. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
15. Thromboembolism in pregnancy and its management
16. Hyperestrogenism induced by menotropins alone or in conjunction with luprolide acetate in vitro fertilization cycles: The impact on hemostasis
17. The influence of hyperestrogenism during in vitro fertilization on the fibrinolytic mechanism
18. Deep vein thrombosis during administration of HMG for ovarian stimulation
19. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: A randomized cross-over study of two low-dose oral contraceptives
20. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: A cross-over study
21. A prothrombinase-based assay for detection of resistance to activated protein C
22. Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals
23. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism
24. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)
25. Low-dose oral contraceptives and acquired resistance to activated protein C: A randomised cross-over study
26. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives
27. Evaluation of a new generation of oral contraceptives
28. Thromboembolic disease associated with ovarian stimulation and assisted conception techniques
29. Haemostasis in normal pregnancy
30. Detection of marked reduction of sensitivity to activated protein C prior to the onset of thrombosis during puerperium as detected by endogenous thrombin potential-based assay
31. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways
32. Influence of hormone replacement therapy, oral contraceptives and pregnancy on APC resistance
33. Third-generation oral contraceptive and deep venous thrombosis: From epidemiologic controversy to new insight in coagulation
34. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study
35. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease
36. Response to activated protein C during normal menstrual cycle and ovarian stimulation